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A unique presentation of Takayasu’s arteritis in a
39-year-old male with chest pain, vertigo, and
blindness
Mustafa D. Nazzal, MD,a Mouchammed Agko, MD,a Karen Zingale, MD,a Masia Hamdan, MD,a
Jonathan A. Higgins, MD,a and Paul Clark, MD,b Toledo, Ohio
Takayasu’s arteritis is a rare form of aortic vasculitis, typically described in young Asian females. In this article, we report
a unique presentation of type V Takayasu’s arteritis in a Hispanic male. To the best of our knowledge, this is the first case
of Takayasu’s arteritis presenting with the triad of angina, amaurosis fugax, and subclavian steal syndrome. On diagnostic
imaging, he was found to have left subclavian and axillary artery stenosis requiring balloon angioplasty. The patient
responded to the combination of medical and surgical treatment with full recovery. (J Vasc Surg 2011;54:529-32.)
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aTakayasu’s arteritis (TA) was named after the Japanese
ophthalmologist Dr. Mikito Takayasu who, in 1908, first
described the syndrome in young Asian females.1 TA is a
chronic granulomatous vasculitis of the aorta and its
branches that may lead to stenosis, occlusion, or aneu-
rysmal dilatation of the involved arteries. We present an
adult male patient with no prodrome who complained of
vertigo, nausea, temporary left-sided blindness, and
chest pain on exertion. He was ultimately diagnosed with
type V TA with subclavian steal syndrome due to left
subclavian and axillary artery stenosis.
This was managed with balloon angioplasty, corticoste-
roid, and antiplatelet therapy.
CASE REPORT
A previously healthy 39-year-old Hispanic male presented to
the emergency department complaining of vertigo, diaphoresis,
intermittent pain in his left upper extremities, chest pain, and
shortness of breath that worsened with exertion, indicating possi-
ble subclavian steal syndrome. He also reported a recent episode of
amaurosis fugax in his left eye. This was complete and had resolved
minutes after onset possibly due to atheroemboli from the left
internal carotid artery. He denied any constitutional symptoms.
The patient’s past medical history was significant only for un-
treated labile hypertension.
Focused vascular examination revealed a right carotid bruit
and a weak left carotid pulse. The left radial pulse was not palpable,
and the systolic blood pressure measured on the right arm was 55
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doi:10.1016/j.jvs.2010.12.059m Hg higher in comparison with the left arm. The erythrocyte
edimentation rate was elevated at 50 mm/h, and C-reactive
rotein measured 1.7 mg/dL (normal, 0-0.5). The patient tested
egative for hepatitis B, C, p-anti-neutrophil cytoplasmic anti-
ody, and c-anti-neutrophil cytoplasmic antibody. He had a nor-
al serum lipid profile and fasting blood glucose level. Electrocar-
iogram, cardiac enzymes, and echocardiogram were also within
ormal limits. Magnetic resonance angiography indicated com-
lete occlusion of the left common carotid artery and high-grade
tenosis of the left subclavian artery (Fig 1). A carotid Doppler
ltrasound showed severe calcific plaque formation in the right
nternal carotid and lack of flow in the left common carotid artery
ith retrograde flow in the left external carotid and vertebral
rteries.
Due to the presence of limb ischemia and signs of vertebro-
asilar insufficiency, the decision was made to intervene surgi-
ally. An angiogram of the aorta and its main branches demon-
trated mild dilatation over the right carotid bulb, occlusion of
he left common carotid artery, multiple collaterals over bilat-
ral shoulders and neck (more evident on the left), and stenosis
f the left subclavian and axillary artery (Fig 2). The cerebral
ngiogram showed that bilateral anterior and middle cerebral
rteries were supplied by the right carotid artery. We could not
dentify any retrograde flow in the left vertebral artery. The right
ertebral artery appeared to be patent. Unfortunately, the circle
f Willis could not be well visualized. Abdominal aortic angio-
ram revealed 50% proximal stenosis of bilateral renal arteries
nd irregularity in the infrarenal aorta (Fig 3). The patterning of
he vascular changes in combination with multiple smooth
egmental stenoses indicated a diagnosis of TA. After arterial
ccess was gained through the left brachial artery, a repeat
ngiogram confirmed prior findings. Balloon angioplasty of
oth the left subclavian and axillary arteries was performed
sing a 7-mm  2-cm balloon, and a 4-mm  8-cm balloon
Boston Scientific, Natick, Mass), respectively. The diameter of
he balloon used in angioplasty was equal to the estimated
iameter of the artery with a pressure of 6 to 8 atm used for
ilation. We elected to use these parameters in order to avoid
rterial rupture during angioplasty. Completion angiography
howed widely patent left subclavian and axillary arteries with
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August 2011530 Nazzal et alantegrade flow in the left vertebral artery. Postoperatively,
systolic blood pressure in the affected arm normalized, and the
patient’s subclavian steal symptoms resolved. The patient was
discharged home a week later on prednisone 30 mg orally for 2
weeks, which was then tapered while monitoring erythrocyte
sedimentation rate and C-reactive protein. Also, an antiplatelet
agent, namely clopidogrel, was started due to presence of
Fig 1. Magnetic resonance angiography demonstrating total oc-
clusion of the left common carotid artery (arrowhead) and high-
grade stenosis of the left subclavian artery (arrow).
Fig 2. Left subclavian angiogram confirming the high-grade ste-
nosis of the left subclavian artery (arrowhead) and delineating an
axillary artery stenosis (arrow).cerebrovascular symptoms. pThe patient was followed up for 1 year with no symptoms of
ertebrobasilar insufficiency on the left side, although he devel-
ped new stenotic lesions at previously uninvolved arteries.
ISCUSSION
TA is known as the “pulseless disease” due to the com-
on sign of a diminished or absent pulse in one or more of the
pper extremities2 prior to vascular involvement; it is usually
receded by a prodrome of fever, weight loss, arthralgia, and
alaise. The typical age of onset of TA is the second or third
ecade of life, and it is nine times more prevalent in females
han males. The estimated prevalence in the United States is
.6 cases per million. However, increased prevalence is noted
n India, Mexico, Japan, and South East Asia.3
The precise pathophysiology has not yet been elucidated,
ut cell-mediated autoimmunity may play a role.4 Many
ausal agents have been proposed in the development of TA,
ncluding tuberculosis, viral hepatitis, infectious mononucle-
sis, chronic inflammation, hyperlipidemia, and environmen-
al toxins; however, no reproducible causal relationship has
een determined for any of these. The most current evidence
uggests that an increased expression of heat shock protein 60
n combination with a special population of T cells increased
n TA patients leads to a cytotoxic reaction and eventual
amage of the aortic endothelium.5 Due to its inflammatory
ature, TA has been associated with accelerated atherosclero-
is as evident in our patient by the presence of calcific plaques.6
The chronic and progressive nature of TA makes early
etection important and potentially alters treatment and
rognosis.7 Delayed diagnosis could have contributed to the
ncreased morbidity and poorer outcomes reported in the
nited States compared to the Far East,8 suggesting that a
tandardized approach to both diagnosis and treatment may
ig 3. Detail of abdominal aortic angiogram showing bilateral
roximal renal artery stenosis of approximately 50%; inferior right
enal artery (arrow) and left renal artery with poststenotic dilation
arrowhead). Of note, duplicated renal arteries are visualized on
he right.rovide benefit.
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Volume 54, Number 2 Nazzal et al 531The diagnosis of TA is largely based on clinical and
radiological findings. Pathologic examination of a biopsy
specimen is nonspecific, as other vasculitides may mimic the
histopathology. There have been several attempts to standard-
ize the diagnosis, including Ishikawa’s Criteria, Sharma’s Cri-
teria (modified Ishikawa), and the American College of Rheu-
matology Criteria.9 After diagnosis, the disease can be further
classified angiographically according to the International
Conferences on Takayasu Arteritis standards. Type I lesions
involve the aortic branches. Type IIa lesions affect the ascend-
ing aorta, the aortic arch, and its branches. Type IIb lesions
include the descending thoracic aorta, as well as the ascending
aorta, the aortic arch, and its branches. While type III lesions
affect the descending thoracic and abdominal aorta along with
the renal arteries, type IV lesions mainly affect the abdominal
aorta and renal arteries. Type V is a combination of types IIb
and IV.10,11 Type I disease of the aortic branches is the most
common, consistent with Ishikawa’s hypothesis that the dis-
ease begins in the left subclavian artery and subsequently
extends to other sites.9
Common presentations of TA include constitutional
symptoms, limb claudication, disparate limb blood pressure/
pulses, hypertension, and dizziness. Generally, a prodromic
inflammatory phase with systemic symptoms precedes the
pulseless, fibrotic phase with vascular symptoms.
Imaging advances have provided physicians with the po-
tential to diagnose TA earlier with more certainty and less risk
to the patient. Recently, less invasive imaging modalities,
including magnetic resonance angiography and computed
tomography angiography, are emerging as diagnostic tools,
with positron emission tomography and Doppler ultrasound
being utilized for surveillance.
Magnetic resonance or computed tomography angiogra-
phy are now preferred by many due to the ability to administer
intravenous rather than arterial contrast, improved resolution,
soft tissue visualization, and wider field of vision. Magnetic
resonance angiography T2 imaging provides particular detail
regarding tissue edema, helping to identify active lesions.
Doppler ultrasonography can document reversal of flow as
seen in steal syndromes. 18F-fluorodeoxyglucose positron
emission tomography has recently been studied as a means to
track progression and recurrence of disease since it displays
areas of active inflammation as hypermetabolic foci.12
Treatment of patients with TA has historically been
with corticosteroid therapy, with escalation to immunosup-
pressive agents, such as methotrexate or cyclophosphamide
for treatment-resistant disease. Recently, infliximab has
been shown to be effective in preventing relapse and main-
taining remission, but further study is needed to determine
the safety and efficacy of this treatment.13 It has been
suggested that steroids and cyclophosphamide are effective
during the early acute phase when surgical management is
usually not preferred. However, these medications lack the
same efficacy in the fibrotic phase when surgical interven-
tion is often required.14 The following four criteria have
been put forth by the National Institutes of Health for
monitoring disease activity: the presence of systemic signs
and symptoms not attributable to another condition, thelevation of acute-phase reactants (erythrocyte sedimenta-
ion rate, C-reactive protein) in absence of another process,
he onset of signs or symptoms of vascular insufficiency,
nd vascular lesions in previously unaffected territories.15
Surgical management is usually deferred in the acute
hase unless severe symptoms exist, as in the current case.
espite available medical treatment, 50% of patients will
rogress to a stage requiring one or more surgical proce-
ures. The indications for surgical therapy in TA are still
nclear. Renovascular hypertension, extremity ischemia,
erebrovascular insufficiency, and dilated ascending aorta
ith aortic regurgitation are acceptable indications.15
Surgical approaches include balloon angioplasty and
utologous bypass grafting from nonaortic branch arteries.
hese methods are associated with varying degrees of suc-
ess.16 The long-term impact of percutaneous transluminal
ngioplasty is still unknown as no studies have evaluated the
ong-term results. However, stenting should be avoided in
A, as it can potentially lead to enhanced myointimal
roliferation, which in turn can lead to luminal occlusion.17
ypass grafting is safe and effective, but is reserved for the
brotic phase as it carries a high risk of complication during
he acute phase.18 In the case we present, after considering
he patient’s low risk of embolization due to his young age
nd the presence of active disease, we opted for angioplasty.
ONCLUSION
TA is an uncommon disease posing both a diagnostic
nd a therapeutic challenge. Increased awareness of this
ondition leading to timely diagnosis and appropriate treat-
ent may improve outcomes in this rare, yet potentially
evastating, disease. Although medical treatment is the
ainstay for treating TA, it is crucial to understand the
ndications for and available options of surgical interven-
ions.
This case demonstrates that percutaneous angioplasty
s a viable option during the active phase of the disease for
he acutely symptomatic young patient who has failed
edical treatment. This does not preclude future bypass
urgery, if required.
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